Oxford Science Enterprises
VC Fund
Oxford, United Kingdom
Oxford Science Enterprises is a VC fund in Oxford focused on Health Care and Biotechnology. Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
- Total investments:
- 196
- Last investment:
- Lead investor:
- 39%
- Fund size:
- $327M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Oxford Science Enterprises invests in
Stages Oxford Science Enterprises invests in
Countries Oxford Science Enterprises invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.4M–$12M
- Series A
- $6.3M–$45M
- Series B
- $13M–$168M
Investment Focus
Industry
- Health Care 28 (14%)
- Biotechnology 25 (13%)
- Software 13 (7%)
- Medical 11 (6%)
- Life Science 11 (6%)
Stage
- Seed 49 (25%)
- Series A 44 (22%)
- Series B 16 (8%)
- Funding Round 15 (8%)
- Series C 5 (3%)
Country
- United Kingdom 73 (37%)
- United States 3 (2%)
- Finland 1 (1%)
- The Netherlands 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexis Dormandy
Chief Executive Officer
|
Chief Executive Officer | Total investments: 1 | Find email | |
|
Alexis Zervoglos
Senior Partner (Technology)
|
Senior Partner (Technology) | Total investments: 3 | Find email | |
Claire Brown
Partner ( Life Sciences)
|
Partner ( Life Sciences) | Total investments: 3 | Find email | |
Ekaterina Smirnyagina
Senior Partner and Head of Life Sciences
|
Senior Partner and Head of Life Sciences | Total investments: 6 | Find email | |
David Norwood
Chairman
|
Chairman | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Mirae
|
Mirae provides an AI-powered patient companion and precision medicine platform for people living with complex chronic diseases, beginning with inflammatory bowel disease. Its mobile application lets users record symptoms, food, medications, laboratory results, and other health information. The platform can connect permitted electronic healthrecords and wearable data to help users review possible patterns and prepare summaries for healthcare appointments. Mirae also develops disease and symptom models that analyze patient-reported and clinical events for healthcare organizations and research activities. The platform does not provide medical diagnosis, prescriptions, or clinical care. | $5.4M / Seed / Jul 28, 2026 | |
Vivid Dx
|
Vivid Dx is a diagnostics company that focuses on pathogen detection and antimicrobial resistance testing services. | $15M / Seed / Jul 28, 2026 | |
MoA Technology
|
MoA Technology Limited is a plant genetics company spun out from the University of Oxford. Professor Liam Dolan, FRS, has developed an innovative approach for the discovery of agricultural technologies that will enable farmers to produce healthy food from sustainable crop systems. | $29.7M / Series C / Jul 23, 2026 | |
RQ Bio
|
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The company's mission is to deliver "instant immunity" through passiveimmunization, helping protect vulnerable populations such as the elderly, newborns, and immunocompromised patients from severe infectious diseases. The company specializes in the discovery and development of broad-spectrum antiviral antibodies that are engineered to remain effective even as viruses evolve. Its scientific approach combines virology, antibody engineering, computational biology, and immune-directed discovery techniques to identify potent antibodies that target conserved regions of viral proteins, reducing the risk of resistance caused by viral mutations.RQ Bio's lead programs focus on infectious diseases such as influenza, COVID-19, respiratory syncytial virus (RSV), and cytomegalovirus (CMV). The company is currently developing long-acting monoclonal antibodies designed to provide once-yearly protection against seasonal influenza, particularly for individuals at high risk of severe disease. | $112.5M / Series A / Jun 24, 2026 | |
Applied Atomics
|
Applied Atomics is a Rapid Response Network in Space. | $4M / Pre-Seed / Jun 10, 2026 | |
Oxford Quantum Circuits
|
Oxford Quantum Circuits developing technology using the power of quantum to do things which have never been achieved before, from enabling life-changing drug discoveries to developing new battery technologies. | $350M / Series C / Jun 03, 2026 | |
Caudal Energy
|
Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics. | $5.8M / Seed / May 27, 2026 | |
Re-Aim Therapeutics
|
Re‑Aim Therapeutics is a UK‑based biotech start‑up developing functional cures for T cell–mediated autoimmune diseases by selectively depleting pathogenic T‑cell subsets. Its lead asset, REA‑001, is a monoclonal antibody designed to potently and precisely eliminate disease‑causing type‑17 T cells, aiming to reset the immune system and achievedurable, treatment‑free remission in multiple autoimmune conditions. | $9.4M / Seed / May 18, 2026 | |
Fractile
|
Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale. | $220M / Series B / May 13, 2026 | |
Quantum Motion
|
Quantum Motion Technologies is building a universal quantum computer in Silicon, using CMOS compatible processes. | $163.5M / Series C / May 07, 2026 | |
| See all 196 investments → | |||
Co-Investors
Oxford Science Enterprises
120 deals together
Parkwalk Advisors
23 deals together
University of Oxford
23 deals together
Oxford University Innovation
19 deals together
IP Group
18 deals together
Oxford Investment Consultants LLP
18 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Oxford Science Enterprises invest in?
Oxford Science Enterprises invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 196 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Oxford Science Enterprises's check size?
Oxford Science Enterprises typically joins rounds of $1.4M–$12M at Seed, $6.3M–$45M at Series A and $13M–$168M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Oxford Science Enterprises participates in.
How do I contact Oxford Science Enterprises?
Public channels for Oxford Science Enterprises include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oxford Science Enterprises?
The team at Oxford Science Enterprises includes Alexis Dormandy (Chief Executive Officer), Alexis Zervoglos (Senior Partner (Technology)) and Claire Brown (Partner ( Life Sciences)), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
